F Star Therapeutics Inc (FSTX) Return on Equity ROE from the third quarter 2022 to third quarter 2021 and annually, average high and low, overall ranking from Sep 30 2022 to Sep 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
F star Therapeutics Inc   (NASDAQ: FSTX)

F Star Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for F Star Therapeutics Inc in the third quarter 2022?
F Star Therapeutics Inc recorded a cumulative net loss of $-44 million during 12 months ending in the third quarter 2022, resulting in a negative return on equity (ROE) of -56.71%.

Within the Major Pharmaceutical Preparations industry 250 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3704, from total ROE ranking in the second quarter 2022 at 3720.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter
Y / Y Equity Change -36.79 % -27.63 % 153.05 % 125.28 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -44 -37 -34 -31 -42
Return On Equity (TTM) -56.71 % -42.51 % -35.82 % -39.01 % -62.72 %
FSTX's Total Ranking # 3704 # 3720 # 3675 # 4206 # 3807
Equity (TTM) in Millions 57 72 88 97 90
Seq. Equity Change -20.52 % -18.75 % -8.98 % 7.53 % -9.01 %
Seq. Net Income Change - - - - -

Back to FSTX Management Effectiveness >> FSTX's 5 Years Annual ROE >> Compare FSTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 251
Sector # 577
Overall # 3704

Return On Equity Statistics
High Average Low
-35.82 %
-550.13 %
-11088.61 %
(Mar 31 2022)   (Sep 30 2020)





FSTX Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions 97 43 36 56 35
Y / Y Equity Change 125.28 % 21.02 % -36.4 % 60.76 % 104.18 %
Net Income in Millions -31 -26 -24 -23 -28
Y / Y Net Income Change - - - - -
Return On Equity -32.3 % -59.59 % -67.83 % -40.91 % -79.66 %

Back to FSTX Management Effectiveness >> FSTX's 5 Years Annual ROE >> Compare FSTX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FSTX's' Return on Equity at Yahoo Finance
FSTX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FSTX's Competitors
Subscribers only: Roe for F Star Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for FSTX's Customers




Companies with similar Return On Equity at Sep 30 2022, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.